Literature DB >> 24681875

Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?: Clinicopathological analysis of 82 long-term survivors.

Sang Hyun Shin1, Song Cheol Kim, Seung-Mo Hong, Ki-Byung Song, Jae Hoon Lee, Kwang-Min Park, Young-Joo Lee.   

Abstract

OBJECTIVE: The objective of this study were to analyze and describe the clinicopathological characteristics of long-term pancreatic ductal adenocarcinoma survivors and to determine if statistically identified prognostic factors can be used to predict the actual survival.
METHODS: Between January 2000 and December 2007, 537 patients with resectable pancreatic ductal adenocarcinoma underwent surgical resection at a single institute. Medical records were retrospectively reviewed, and 9 patients were excluded. Of the remaining 528, patients who survived for more than 5 years were classified as long-term survivors.
RESULTS: The actual 5-year survival rate of all 528 included patients was 15.5% (82 patients; median follow-up period, 82.7 months). Fifty-eight patients (70.7%) were diagnosed with cancers located in the head of pancreas, and the median size was 2.5 cm (range, 0.8-12.0 cm). Three patients had focal involvement noted on the resected surfaces. Poorly differentiated carcinoma (9.8%), lymph node metastasis (32.9%), lymphovascular invasion (25.6%), and perineural invasion (48.8%) were detected. Fifty-five of the 82 long-term survivors whose clinicopathological characteristics included several dismal predictors survived for more than 5 years without recurrence.
CONCLUSIONS: The long-term survivors identified in this study did not meet the appropriate prognostic criteria. Therefore, there are limitations in the use of statistically determined prognostic factors for estimating in the long term.

Entities:  

Mesh:

Year:  2014        PMID: 24681875     DOI: 10.1097/MPA.0000000000000063

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival.

Authors:  Steven Walczak; Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2017-08-03       Impact factor: 3.452

Review 2.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Long-term survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Alexander P Stark; Greg D Sacks; Matthew M Rochefort; Timothy R Donahue; Howard A Reber; James S Tomlinson; David W Dawson; Guido Eibl; O Joe Hines
Journal:  Surgery       Date:  2016-02-02       Impact factor: 3.982

4.  Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.

Authors:  Christelle d'Engremont; Dewi Vernerey; Anne-Laure Pointet; Gaël Simone; Francine Fein; Bruno Heyd; Stéphane Koch; Lucine Vuitton; Stefano Kim; Marine Jary; Najib Lamfichek; Celia Turco; Zaher Lakkis; Anne Berger; Franck Bonnetain; Julien Taieb; Philippe Bachellier; Christophe Borg
Journal:  BMC Cancer       Date:  2016-10-26       Impact factor: 4.430

5.  Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma.

Authors:  Dingyuan Hu; Daniel Ansari; Krzysztof Pawłowski; Qimin Zhou; Agata Sasor; Charlotte Welinder; Theresa Kristl; Monika Bauden; Melinda Rezeli; Yi Jiang; György Marko-Varga; Roland Andersson
Journal:  Oncotarget       Date:  2018-01-03

6.  The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data.

Authors:  Axel Bengtsson; Roland Andersson; Daniel Ansari
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

7.  Resected pancreatic adenocarcinoma: An Asian institution's experience.

Authors:  Kennedy Yao Yi Ng; Edwin Wei Xiang Chow; Bochao Jiang; Cindy Lim; Brian Kim Poh Goh; Ser Yee Lee; Jin Yao Teo; Damien Meng Yew Tan; Peng Chung Cheow; London Lucien Peng Jin Ooi; Pierce Kah Hoe Chow; Joycelyn Jie Xin Lee; Juinn Huar Kam; Ye Xin Koh; Prema Raj Jeyaraj; Ek Khoon Tan; Su Pin Choo; Chung Yip Chan; Alexander Yaw Fui Chung; David Tai
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.